Bruker Corporation (BRKR)
NASDAQ:BRKR
Top Page
Bruker
(NASDAQ:BRKR)
Select Model
Select Model
Rating:50Neutral
Price Target:
$36.00
▼(-5.88% Downside)
Action:ReiteratedDate:04/02/26
The score is held back primarily by weakened TTM fundamentals (revenue decline, margin compression, and materially softer cash flow) and a bearish technical setup (below key moving averages with negative MACD). Guidance and order/backlog signals from the latest call provide some support via a credible margin-recovery plan and improved demand indicators, but valuation support is limited with a negative P/E and only a modest dividend.
Positive Factors
Growing recurring/aftermarket revenue
A larger aftermarket mix (38% of BSI) increases recurring revenue and lessens reliance on lumpy instrument sales. Over the next 2–6 months this supports steadier cash flow, higher lifetime customer value, and more predictable margins as installed base monetization scales.
Negative Factors
Persistent organic revenue declines
Ongoing organic declines signal structural demand weakness in key end markets and reduce the predictability of instrument-led revenue. If organic trends continue, reliance on M&A and FX tailwinds to meet growth targets raises execution risk and pressures sustainable topline recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Growing recurring/aftermarket revenue
A larger aftermarket mix (38% of BSI) increases recurring revenue and lessens reliance on lumpy instrument sales. Over the next 2–6 months this supports steadier cash flow, higher lifetime customer value, and more predictable margins as installed base monetization scales.
Read all positive factors
Bruker (BRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.82B
Dividend Yield0.42%
Average Volume (3M)2.00M
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth6.10%
EPS Growth-107.47%
CountryUS
Employees11,396
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.59
Shares Outstanding152,219,250
10 Day Avg. Volume1,612,998
30 Day Avg. Volume1,996,241
Financial Highlights & Ratios
PEG Ratio6.94
Price to Book (P/B)2.91
Price to Sales (P/S)2.08
P/FCF Ratio165.16
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda25.46
Forecast
1Y Price Target
$43.50Price Target Upside13.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)2.11
Revenue Forecast (FY)$3.58B
Bruker Business Overview & Revenue Model
Company Description
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) L...
How the Company Makes Money
Bruker primarily makes money by selling scientific instruments and integrated analytical systems, complemented by recurring revenue from services, software, and consumables. Key revenue streams typically include: (1) Instrument and system sales: O...
Bruker Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Neutral
Balanced/Neutral: The company showed meaningful positives including a Q4 revenue beat, exceptional cash generation (Q4 operating cash flow of ~$230M, free cash flow $207M), strong order momentum (BSI book-to-bill >1.0, ~7 months backlog), large multiyear BEST orders (> $500M), and constructive FY2026 guidance with targeted margin expansion and raised cost-savings expectations. However, these positives are offset by material near-term challenges: persistent organic revenue declines (Q4 -5.1%, FY -3.7%), significant margin compression (Q4 non-GAAP operating margin down 240 bps), pressure from tariffs and FX, weak U.S. academic/government funding, and expected Q1 2026 organic decline. Taken together, the call presents a credible operational and financial recovery plan built on strong cash flow and order momentum, but also substantial short-term headwinds and execution/timing risks.Positive Updates
Q4 Revenue Beat and Reported Revenue
Q4 2025 reported revenue of $977.2M was roughly flat year-over-year and came in about $20M above company expectations; full-year 2025 reported revenue was $3.44B, up 2.1% versus 2024.
Negative Updates
Organic Revenue Declines
Organic revenue declined 5.1% in Q4 2025 and declined 3.7% for full-year 2025, with organic declines of 5.1% in both BSI and BEST in Q4; several groups and end markets saw mid- to high-single-digit organic weakness.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue Beat and Reported Revenue
Q4 2025 reported revenue of $977.2M was roughly flat year-over-year and came in about $20M above company expectations; full-year 2025 reported revenue was $3.44B, up 2.1% versus 2024.
Read all positive updates
Company Guidance
Bruker guided fiscal 2026 reported revenue of $3.57–$3.60 billion (growth 4%–5%), comprised of 1%–2% organic growth, ~1.5% from M&A and an estimated ~1.5% FX tailwind (implying ~2.5%–3.5% constant‑currency revenue growth), while Q1 2026 organic revenue is expected down mid‑single‑digits with organic growth resuming in Q2; they noted a BSI backlog of ~7 months and two consecutive quarters of BSI book‑to‑bill >1.0. Management expects non‑GAAP operating margin expansion of 250–300 bps in 2026 (including ~50 bps currency headwind, implying ~300–350 bps organic margin improvement versus FY2025’s 12.6%), non‑GAAP EPS of $2.10–$2.15 (15%–17% reported growth, ~8% / ~$0.15 FX headwind, implying 23%–25% CER EPS growth), and cost savings now expected to exceed the prior $100–$120M target (approaching ~$140M+ annualized); Q4 free cash flow was $207M.Bruker Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
66
Positive
Cash Flow
44
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.44B | 3.37B | 2.96B | 2.53B | 2.42B |
| Gross Profit | 1.57B | 1.65B | 1.51B | 1.31B | 1.21B |
| EBITDA | 287.50M | 438.60M | 675.50M | 518.70M | 497.10M |
| Net Income | -8.60M | 113.10M | 427.20M | 296.60M | 277.10M |
Balance Sheet | |||||
| Total Assets | 6.24B | 5.81B | 4.25B | 3.61B | 3.65B |
| Cash, Cash Equivalents and Short-Term Investments | 298.80M | 183.40M | 488.30M | 645.50M | 1.17B |
| Total Debt | 2.04B | 2.25B | 1.38B | 1.27B | 1.39B |
| Total Liabilities | 3.73B | 3.99B | 2.84B | 2.48B | 2.57B |
| Stockholders Equity | 2.46B | 1.78B | 1.38B | 1.11B | 1.07B |
Cash Flow | |||||
| Free Cash Flow | 43.30M | 136.00M | 243.20M | 145.20M | 190.40M |
| Operating Cash Flow | 134.10M | 251.30M | 350.10M | 274.40M | 282.40M |
| Investing Cash Flow | -196.50M | -1.76B | -326.00M | -251.60M | -192.40M |
| Financing Cash Flow | 135.10M | 1.23B | -193.40M | -415.30M | 318.70M |
Bruker Technical Analysis
Neutral
38.25
Price Trends
38.36
Negative
43.00
Negative
39.73
Negative
Market Momentum
-0.39
Negative
57.78
Neutral
78.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Neutral. The current price of 38.25 is above the 20-day moving average (MA) of 35.16, below the 50-day MA of 38.36, and below the 200-day MA of 39.73, indicating a neutral trend. The MACD of -0.39 indicates Negative momentum. The RSI at 57.78 is Neutral, neither overbought nor oversold. The STOCH value of 78.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BRKR.
Bruker Risk Analysis
Bruker disclosed 42 risk factors in its most recent earnings report. Bruker reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bruker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $12.42B | 21.94 | 12.40% | ― | 11.75% | 364.73% | |
68 Neutral | $3.54B | -13.83 | -21.49% | ― | 8.97% | -1024.86% | |
66 Neutral | $3.01B | 26.50 | 6.05% | ― | 7.81% | -26.32% | |
64 Neutral | $7.59B | 2.84 | 10.86% | ― | -0.88% | 10.93% | |
59 Neutral | $6.89B | -34.40 | -25.41% | ― | 30.38% | 47.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $5.82B | ― | -0.40% | 0.42% | 6.10% | -107.47% |
* Healthcare Sector Average
BRKR
Bruker
38.25
-2.72
-6.64%
BIO
Bio-Rad Laboratories
281.15
31.98
12.83%
ITGR
Integer Holdings
87.48
-28.89
-24.83%
GMED
Globus Medical
91.96
17.68
23.80%
GKOS
Glaukos
118.62
25.07
26.80%
LIVN
LivaNova
64.66
28.94
81.02%
Bruker Corporate Events
Business Operations and StrategyExecutive/Board Changes
Bruker Expands Board, Appoints Thierry Bernard as Director
Positive
Apr 1, 2026
On March 27, 2026, Bruker’s board voted to expand its size to 12 members and appointed Thierry L. Bernard, CEO and Managing Director of QIAGEN N.V., as a Class III director effective April 1, 2026, with a term running until the 2027 annual m...
Executive/Board ChangesDividends
Bruker Announces Board Changes and Declares Quarterly Dividend
Positive
Feb 20, 2026
On February 16, 2026, Bruker said board member Dr. Cynthia M. Friend will retire from the Board of Directors at the 2026 Annual Meeting when her current term as a Class II director expires, after serving since May 2016 and sitting on the Compensat...
Regulatory Filings and Compliance
Bruker clarifies regulatory filing status in recent 8-K
Neutral
Jan 12, 2026
In a recent regulatory filing, Bruker clarified that certain information furnished in Item 2.02 and Item 7.01 of its current report on Form 8-K is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and will not auto...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.